Your SlideShare is downloading. ×
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

320
views

Published on

Renub Research has announced the addition of the "Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” report to its …

Renub Research has announced the addition of the "Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” report to its offering



Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide - Market Overview

Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care.

Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters.

A. Hepatitis C Drugs Market & Forecast (Chapter 2)
B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
C. Hepatitis C Deals & Acquisitions (Chapter 4)
D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5)
E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6)
F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)

Published in: Health & Medicine, Business

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
320
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
16
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Hepatitis C Drugs – Market & Forecast from 2010 to 2018 Global – Forecast for Hepatitis C Drug Market (Million US$), 2013 – 2018 Source: Given in the report Renub Research www.renub.com
  • 2. Order the report & get - Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide A comprehensive 164 page report, supported by data-rich 25 Figures and 2 Tables Renub Research www.renub.com
  • 3. Data Available for –Pegasys, Pegintron, Incivek, Victrelis Sales & Forecast from 2005 to 2018 Global – Pegasys Sales (Million US$), 2005 – 2012 Source: Given in the report Renub Research www.renub.com
  • 4. The Following Pipeline Drugs Clinical Trials (Drugs in Phase III) covered in the report • Simeprevir (TMC 435) (Company: Janssen Pharmaceutical) • Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim) • Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb) • Sofosbuvir (PSI-7977 or GS7977) (Company: Gilead Sciences) • Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb) • BI-207127 (Company: Boerhinger Ingelheim) • ABT-267 (Company: Abbott Laboratories) • ABT-072/333 (Company: Abbott Laboratories) • Alisporivir (Company: Novartis) Renub Research www.renub.com
  • 5. The Following Pipeline Drugs Clinical Trials (Drugs in Phase II) covered in the report • Mericitabine (RG7128) (Company: Roche) • Danoprevir/r (Ritonavir) (RG7227) (Company: Roche) • GS-9256 (Company: Gilead Sciences) • MK-5172 (Company: Merck) • Sovaprevir (ACH-1625) (Company: Achillion) • • • • IDX-320 (Company: Idenix) MK-8742 (Company: Merck) IDX-719 (Company: Idenix) Setrobuvir (ANA-598) (Company: Roche) • GS-9669 (Company: Gilead Sciences ) • GS-9190 (Tegobuvir) (Company: Gilead Sciences) • BMS-791325 (Company: Bristol-Myers Squibb) Renub Research www.renub.com
  • 6. The following pipeline drugs sales covered in the report : Simeprevir (TMC 435), Faldaprevir (BI 201335), Asunaprevir (BMS650032), Sofosbuvir (PSI-7977 or GS-7977) from 2014 to 2018 Global – Forecast for Simeprevir (TMC 435) Sales (Million US$), 2014 – 2018 Source: Given in the report Renub Research www.renub.com
  • 7. The following pipeline drugs sales covered in the report : Daclatasvir (BMS-790052), ABT-450/r (Ritonavir), ABT072/333, Alisporivir, Danoprevir (RG7227), GS-9256, VX-222 from 2014 to 2018 Global – Forecast for Daclatasvir (BMS-790052) Sales (Million US$), 2014 – 2018 Source: Given in the report Renub Research www.renub.com
  • 8. Order Form Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780 Questions? Please call +1-678-302-0700 (USA) +91-120-421-9822 (India), ,+91-120-424-9780 or mail to info@renub.com Renub Research www.renub.com
  • 9. Format Report Title: Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide For More Details: http://www.renub.com/report/hepatitis-c-market-forecast-hcvdrugs-clinical-trials-hepatitis-c-pipeline-drugs-sales-forecast--worldwide-118 Single User (Email from Publisher) US$ 1,290 Hard Copy CD – Rom (Mail Delivery) (Mail Delivery) US$ 1,440 US$ 1,390 Renub Research Global Site License (Multiple User License) US$ 2,090 www.renub.com
  • 10. For ordering this report: Three easy ways to place your order 1) Order online by Credit Card (Visa, MasterCard, etc.): http://www.renub.com/buyreport/118-1454 2) Order by Wire Transfer: http://www.renub.com/report/wiretransfer.aspx?id=118&pid=1454 To pay by Wire Transfer, please, fill in your contact details in the form below: Renub Research www.renub.com
  • 11. Bank Details Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi – 110001 India Renub Research www.renub.com
  • 12. Contact Information First Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message: Last Name: Renub Research www.renub.com
  • 13. Order by Check Please post the check accompanied by this form, to: Company Address: Renub Research 1st Floor, C-86, Sector-10 Noida - 201301 Uttar Pradesh India Phone: +91-120-421-9822, 424-9780 For free Sample copy report or to view any of our sample work please contact us at info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA) Renub Research www.renub.com

×